Isis, CIR form antisense company

ISIP and incubator company Circadian Technologies (ASX:CIR) formed Antisense Therapeutics (ASX:ANP) to discover and develop antisense compounds. Following ANP's AUS$13 million ($6.8 million) IPO on Wednesday, ISIP and CIR own 14% and 36% of the company, respectively. ANP received a license to ISIP's preclinical ISIS 107248 antisense inhibitor of CD 49d to treat inflammatory diseases, including multiple sclerosis. ISIP will manufacture clinical batches of the compound in exchange for payments. ...